Understanding how metabolism and inflammation affect diabetes in teens
The Role of Circulating Meta-Inflammatory Monocytes in Adolescent Insulin Resistance
This study is trying to see how body weight, lifestyle, and diet affect inflammation and metabolism in teens to better understand diabetes risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 175 (estimated) |
| Ages | 14 Years to 18 Years |
| Sex | All |
| Sponsor | University of Michigan Academic / other |
| Locations | 1 site (Ann Arbor, Michigan) |
| Trial ID | NCT06007404 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect health-related information and blood samples from adolescents to explore the relationship between body composition, lifestyle habits, and diet on meta-inflammatory monocytes (MiMos). The researchers hypothesize that adolescents at risk for metabolic diseases exhibit increased MiMo activity, which may contribute to insulin resistance. By analyzing these factors, the study seeks to provide insights into the mechanisms underlying diabetes and related conditions in this age group.
Who should consider this trial
Good fit: Ideal candidates for this study are adolescents aged 14 to 18 who are at various weight categories or diagnosed with Type 2 Diabetes.
Not a fit: Patients who are currently pregnant or have conditions that affect glucose metabolism may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and prevention strategies for diabetes and metabolic diseases in adolescents.
How similar studies have performed: While this approach is focused on a specific adolescent population, similar studies have shown promise in understanding metabolic diseases and inflammation in other demographics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Between 14 and 18 years of age * Tanner stage 4 or 5 (mature adult stage of puberty) * Normal weight (BMI ≥ 5th percentile \& \< 85th percentile), overweight (BMI \> 86th percentile) \& \< 94th percentile), obese weight (BMI percentile ≥ 95th percentile), and/or pre-diabetes (HbA1c \> 5.7%) * For Type 2 Diabetes cohort, diagnosis of Type 2 Diabetes Exclusion Criteria: * Currently pregnant * Use medications known to affect glucose metabolism (immunosuppressive medications, cancer medications, or high dose steroids), unless prescribed for Type 2 Diabetes management * Prior diagnosis of autoimmune disease, cancer, or a cognitive or perceptual disability that would inhibit following directions of study staff * Allergies or intolerance to milk, soy, or palm oil
Where this trial is running
Ann Arbor, Michigan
- University of Michigan — Ann Arbor, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Kanakadurga Singer, MA, MD — University of Michigan
- Study coordinator: The Singer Lab Team
- Email: MiMoStudy@med.umich.edu
- Phone: (734) 615-4938
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.